Antifibrotic drugs for idiopathic pulmonary fibrosis: What we ...
Currently, there are two antifibrotic drugs that have been approved for the treatment of IPF - pirfenidone and nintedanib 5, 6. However, both of these drugs have modest benefits and only …
The current landscape of antifibrotic therapy across different …
2024年7月1日 · Fibrosis is a common pathological process that can affect virtually all the organs, but there are hardly any effective therapeutic options. This has led to an intense search for …
Targeting metabolic dysregulation for fibrosis therapy
2019年9月23日 · A cellular map of metabolic enzymes and pathways targeted by antifibrosis drugs is shown. Modulation of glycolysis, fatty acid oxidation (FAO) and fatty acid synthesis …
Antifibrosis: to reverse the irreversible - PubMed
No proven antifibrotic therapy has shown efficacy in ameliorating the clinical course of fibrotic diseases, but our current understanding led to the development of different drugs with …
Targeting fibrosis: mechanisms and clinical trials | Signal ...
2022年6月30日 · In fibrosis, the most common type of EMT is the type 2 EMT process. Type 2 EMT, mainly caused by inflammation, is closely related to tissue damage repair response and …
Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis - CHEST
2021年7月1日 · Initiating antifibrotic therapy should be a shared decision between patients and their treating physicians. This process involves a detailed discussion of benefits and risks of …
Antifibrotic treatment improves clinical outcomes in patients ...
2020年9月24日 · This study aimed to investigate the impact of antifibrotic treatment on the risks of mortality, hospitalisation, and acute exacerbation in real-world patients with IPF. A total of …
Antifibrotic Therapies: Where Are We Now? - PubMed
Fibrosis is the wound-healing response of tissues to injury. Extensive characterization of organ fibrosis mechanisms has identified common core pathways in renal, pulmonary, skin, and liver …
Antifibrosis: To Reverse the Irreversible | Clinical Reviews
2009年6月23日 · No proven antifibrotic therapy has shown efficacy in ameliorating the clinical course of fibrotic diseases, but our current understanding led to the development of different …
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to …
2019年9月6日 · Two antifibrotic therapies have been approved for the treatment of IPF: nintedanib and pirfenidone. These drugs slow decline in lung function and reduce the risk of …
- 某些结果已被删除